Drug-controlled CAR T cells through the regulation of cell-cell interactions.

Venetoclax-controlled DROP-CAR T cells effectively regulate tumor targeting and reduce off-tumor toxicity through dose-dependent cell-cell interaction modulation.

• Why it matters: Controlling CAR T cell activity is crucial to minimize toxicities and exhaustion caused by chronic antigen exposure, but current methods lack safe, nonimmunogenic, and clinically approved drug-responsive components.
• What they did: Researchers designed and optimized a human-origin protein-protein interaction (PPI) to create DROP-CARs that respond to venetoclax, enabling precise, dose-dependent release of tumor-targeting components, and demonstrated dual and logic-gated control in vitro and in vivo.
• The result: This approach offers a promising strategy for safer, more effective CAR T cell therapies with potential for clinical translation, by allowing fine-tuned regulation of tumor engagement and immune response.